+

WO2002006300A3 - PF-4 MUTE, SES FRAGMENTS ET PEPTIDES DE FUSION MUTES, LEURS ANALOGUES, LES SEQUENCES D'ADN, ADNc ET ARNm CORRESPONDANTES, ET LEUR UTILISATION DANS L'INHIBITION DE L'ANGIOGENESE - Google Patents

PF-4 MUTE, SES FRAGMENTS ET PEPTIDES DE FUSION MUTES, LEURS ANALOGUES, LES SEQUENCES D'ADN, ADNc ET ARNm CORRESPONDANTES, ET LEUR UTILISATION DANS L'INHIBITION DE L'ANGIOGENESE Download PDF

Info

Publication number
WO2002006300A3
WO2002006300A3 PCT/FR2001/002341 FR0102341W WO0206300A3 WO 2002006300 A3 WO2002006300 A3 WO 2002006300A3 FR 0102341 W FR0102341 W FR 0102341W WO 0206300 A3 WO0206300 A3 WO 0206300A3
Authority
WO
WIPO (PCT)
Prior art keywords
mutated
analogues
fragments
cdna
inhibiting angiogenesis
Prior art date
Application number
PCT/FR2001/002341
Other languages
English (en)
Other versions
WO2002006300A2 (fr
Inventor
Andreas Bikfalvi
Monica Alemany
Original Assignee
Univ Bordeaux 1
Inst Vaisseaux Et Du Sang
Andreas Bikfalvi
Monica Alemany
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Bordeaux 1, Inst Vaisseaux Et Du Sang, Andreas Bikfalvi, Monica Alemany filed Critical Univ Bordeaux 1
Priority to US10/333,364 priority Critical patent/US20040086999A1/en
Priority to EP01955438A priority patent/EP1301534B1/fr
Priority to DE60125944T priority patent/DE60125944D1/de
Priority to CA002416813A priority patent/CA2416813A1/fr
Priority to AU2001277604A priority patent/AU2001277604A1/en
Publication of WO2002006300A2 publication Critical patent/WO2002006300A2/fr
Publication of WO2002006300A3 publication Critical patent/WO2002006300A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention a pour objet un peptide choisi parmi le groupe constitué par le PF-4, les fragments et peptides de fusion dérivés du PF-4, et leurs analogues, présentant une activité inhibitrice de l'angiogenèse, dans lequel la glutamine en position 56 dans le PF-4 natif est remplacée par une arginine, une lysine ou une histidine, de préférence une arginine. Un peptide selon l'invention présente une I50 inférieure à l'I50 du même peptide ne présentant pas de mutation en 56. L'invention a également pour objet les séquences d'ADN ou ADNc codant pour les peptides selon l'une l'invention, et l'utilisation de ses séquences et/ou de ces peptides pour la préparation d'un médicament destiné à l'inhibition de l'angiogenèse et/ou de la prolifération cellulaire.
PCT/FR2001/002341 2000-07-19 2001-07-18 PF-4 MUTE, SES FRAGMENTS ET PEPTIDES DE FUSION MUTES, LEURS ANALOGUES, LES SEQUENCES D'ADN, ADNc ET ARNm CORRESPONDANTES, ET LEUR UTILISATION DANS L'INHIBITION DE L'ANGIOGENESE WO2002006300A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US10/333,364 US20040086999A1 (en) 2000-07-19 2001-07-18 Mutated-pf-4, its fragments and mutated fusion peptides, their analogues, corresponding dna, cdna and mrna sequences and their use for inhibiting angiognesis
EP01955438A EP1301534B1 (fr) 2000-07-19 2001-07-18 PF-4 MUTE, SES FRAGMENTS ET PEPTIDES DE FUSION MUTES, LEURS ANALOGUES, LES SEQUENCES D'ADN, ADNc ET ARNm CORRESPONDANTES, ET LEUR UTILISATION DANS L'INHIBITION DE L'ANGIOGENESE
DE60125944T DE60125944D1 (de) 2000-07-19 2001-07-18 Mutiertes pf4, seine mutierte fragmente und fusionspeptide, deren analoga, zugehörige dna-, cdna- und mrna-sequenzen und deren verwendung zur hemmung der angiogenese
CA002416813A CA2416813A1 (fr) 2000-07-19 2001-07-18 Pf-4 mute, ses fragments et peptides de fusion mutes, leurs analogues, les sequences d'adn, adnc et arnm correspondantes, et leur utilisation dans l'inhibition de l'angiogenese
AU2001277604A AU2001277604A1 (en) 2000-07-19 2001-07-18 Mutated pf-4, its fragments and mutated fusion peptides, their analogues, corresponding dna, cdna and mrna sequences and their use for inhibiting angiogenesis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0009464A FR2811991B1 (fr) 2000-07-19 2000-07-19 Pf-4 mute, ses fragments et peptides de fusion mutes, leurs analogues, les sequences d'adn, adnc et arnm correspondantes, et leur utilisation dans l'inhibition de l'angiogenese
FR00/09464 2000-07-19

Publications (2)

Publication Number Publication Date
WO2002006300A2 WO2002006300A2 (fr) 2002-01-24
WO2002006300A3 true WO2002006300A3 (fr) 2002-04-11

Family

ID=8852683

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2001/002341 WO2002006300A2 (fr) 2000-07-19 2001-07-18 PF-4 MUTE, SES FRAGMENTS ET PEPTIDES DE FUSION MUTES, LEURS ANALOGUES, LES SEQUENCES D'ADN, ADNc ET ARNm CORRESPONDANTES, ET LEUR UTILISATION DANS L'INHIBITION DE L'ANGIOGENESE

Country Status (7)

Country Link
US (1) US20040086999A1 (fr)
EP (1) EP1301534B1 (fr)
AU (1) AU2001277604A1 (fr)
CA (1) CA2416813A1 (fr)
DE (1) DE60125944D1 (fr)
FR (1) FR2811991B1 (fr)
WO (1) WO2002006300A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2287183A1 (fr) 2009-07-29 2011-02-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) Mutants PF4 polypeptides exhibiting an increased anti-angiogenic activity

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0378364A2 (fr) * 1989-01-10 1990-07-18 Repligen Corporation Analogues de PF4 et leurs fragments et compositions pharmaceutiques les contenant
FR2691153A1 (fr) * 1992-05-18 1993-11-19 Serbio Dodécapeptides monomère et dimère, utilisation en tant qu'agents anti-mégacaryocytaires.
WO1997012036A2 (fr) * 1995-09-26 1997-04-03 Gensci Regeneration Sciences Inc. Facteur de stimulation de la croissance osseuse
WO1999041283A1 (fr) * 1998-02-16 1999-08-19 Institut Des Vaisseaux Et Du Sang Fragments de pf4 modifies et compositions pharmaceutiques les renfermant

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0378364A2 (fr) * 1989-01-10 1990-07-18 Repligen Corporation Analogues de PF4 et leurs fragments et compositions pharmaceutiques les contenant
FR2691153A1 (fr) * 1992-05-18 1993-11-19 Serbio Dodécapeptides monomère et dimère, utilisation en tant qu'agents anti-mégacaryocytaires.
WO1997012036A2 (fr) * 1995-09-26 1997-04-03 Gensci Regeneration Sciences Inc. Facteur de stimulation de la croissance osseuse
WO1999041283A1 (fr) * 1998-02-16 1999-08-19 Institut Des Vaisseaux Et Du Sang Fragments de pf4 modifies et compositions pharmaceutiques les renfermant

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JOUAN VALERIE ET AL: "Inhibition of in vitro angiogenesis by platelet factor-4-derived peptides and mechanism of action.", BLOOD, vol. 94, no. 3, 1 August 1999 (1999-08-01), pages 984 - 993, XP002168845, ISSN: 0006-4971 *
LECOMTE-RACLET E A: "New insights into the negative regulation of hematopoiesis by chemokine platelet factor 4 and related peptides", BLOOD,W.B. SAUNDERS, PHILADELPHIA, VA,US, vol. 91, no. 8, 15 April 1998 (1998-04-15), pages 2772 - 2780, XP002148262, ISSN: 0006-4971 *
MAIONE T E ET AL: "INHIBITION OF ANGIOGENESIS BY RECOMBINANT HUMAN PLATELET FACTOR-4 AND RELATED PEPTIDES", SCIENCE,US,AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, vol. 247, no. 49, 5 January 1990 (1990-01-05), pages 77 - 79, XP002027204, ISSN: 0036-8075 *
WALZ A ET AL: "EFFECTS OF THE NEUTROPHIL-ACTIVATING PEPTIDE NAP-2, PLATELET BASIC PROTEIN, CONNECTIVE TISSUE-ACTIVATING PEPTIDE III, AND PLATELET FACTOR 4 ON HUMAN NEUTROPHILS", JOURNAL OF EXPERIMENTAL MEDICINE,TOKYO,JP, vol. 170, 1 November 1989 (1989-11-01), pages 1745 - 1750, XP000943072, ISSN: 0022-1007 *

Also Published As

Publication number Publication date
US20040086999A1 (en) 2004-05-06
AU2001277604A1 (en) 2002-01-30
EP1301534A2 (fr) 2003-04-16
EP1301534B1 (fr) 2007-01-10
CA2416813A1 (fr) 2002-01-24
FR2811991A1 (fr) 2002-01-25
WO2002006300A2 (fr) 2002-01-24
DE60125944D1 (de) 2007-02-22
FR2811991B1 (fr) 2003-01-17

Similar Documents

Publication Publication Date Title
WO2001018035A3 (fr) Peptides derives de muc-1
CA2253636A1 (fr) Polypeptide de la proteine-106 de la membrane externe de moraxella catarrhalis, sa sequence genetique et son utilisation
AUPP051497A0 (en) Antimicrobial peptides
NZ606427A (en) Extended recombinant polypeptides and compositions comprising same
NZ505880A (en) IL-18 receptor polypeptides
EP1092774A3 (fr) Antigène de Borrelia burgdorferi OspA, gène le codant et leur utilisations
WO1998004702A3 (fr) Proteines, notamment proteines membranaires, d'helicobacter pylori, leur preparation et utilisation
ATE424452T1 (de) Polypeptide mit phytase-aktivität
AU2003264708A1 (en) Use of aspartic proteases in cosmetics and therapeutics
EP0349342A3 (fr) Polypeptides ayant une activité dispersante de cellules
WO2003031598A3 (fr) Sequences d'acides nucleiques et d'acides amines codant des polypeptides de facteur viii a expresseur a haut rendement et leurs procedes d'utilisation
CA2491040A1 (fr) Analogues du facteur x a clivage par la thrombine
WO2002070549A3 (fr) Polypeptides chimeriques d'albumine serique et utilisations de ces derniers
EP1006126A3 (fr) Peptide possedant une activité ostéogénique
WO2002006300A3 (fr) PF-4 MUTE, SES FRAGMENTS ET PEPTIDES DE FUSION MUTES, LEURS ANALOGUES, LES SEQUENCES D'ADN, ADNc ET ARNm CORRESPONDANTES, ET LEUR UTILISATION DANS L'INHIBITION DE L'ANGIOGENESE
GB0210783D0 (en) Anti-microbial polypeptides
WO2001053453A3 (fr) Nouveaux acides nucleiques de moelle osseuse et polypeptides associes
AU2865801A (en) Therapeutic peptides
WO2001029224A3 (fr) Homologue zgpa1 de peptide de granulocyte
ATE312923T1 (de) Moraxella catarrhalis basb034 polypeptide und verwendungen davon
SG170092A1 (en) Peptides of regulatory or accessory proteins of hiv, compositions and the utilization thereof
GB2356864B (en) Novel polypeptide
PL345193A1 (en) Basb027 proteins and genes from moraxella catarrhalis
WO2001012665A3 (fr) Cytokine zalpha48 a enroulement en helice
EP0858808A3 (fr) Peptides applicables au traitement de lésions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2416813

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001955438

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001955438

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10333364

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWG Wipo information: grant in national office

Ref document number: 2001955438

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载